Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development

Rhea-AI Summary

Dogwood Therapeutics (NASDAQ: DWTX) announced registered and private offerings to raise up to $12.5 million in upfront gross proceeds and the potential for an additional $14.4 million upon warrant exercises, for aggregate financings tied to issuance of 4,386,037 common shares (or pre-funded warrants) and detachable warrants. Securities are priced at-the-market under Nasdaq rules at a combined purchase price of $2.85 and warrant exercise price of $3.28. Proceeds are earmarked to advance Halneuron through Phase 2b final readout and support further development and working capital.

Positive

• Upfront gross proceeds of $12.5M
• Potential additional $14.4M upon warrant exercise
• Financing explicitly to advance Halneuron Phase 2b and Phase 3 planning
• Registered offering uses an effective Form S-3 shelf registration

Negative

• Issuance of 4,386,037 shares and warrants will dilute existing shareholders
• Warrants exercisable only upon shareholder approval, delaying potential cash
• Combined purchase price of $2.85 signals capital raised at current depressed level

Argus Jan 12 session

+5.61% close to close Open Argus

Details

News Market Reaction – DWTX

On Jan 12, the day this news came out, DWTX closed 5.61% above the previous close.

Data tracked by StockTitan Argus for the Jan 12 session.

Key Figures

Total financing size: $26.8M Upfront gross proceeds: $12.5M Potential warrant proceeds: $14.4M +5 more

Total financing size

$26.8M

Maximum gross proceeds from Registered Offering plus warrant exercises

Upfront gross proceeds

$12.5M

Expected gross proceeds before commissions and expenses

Potential warrant proceeds

$14.4M

Additional gross proceeds if all warrants exercised

Combined offering price

$2.85

Per common share and accompanying warrant in the offerings

New shares / prefunded

4,386,037

Aggregate common shares (or pre-funded warrants) issued

Registered shares component

2,338,948

Common shares issued in the Registered Offering

Pre-funded warrants

2,047,089

Shares underlying pre-funded warrants in Private Offering

Warrant exercise price

$3.28

Per share exercise price for common stock warrants

Historical Context

5 past events · Latest: Dec 22

5 events

1. Dec 22

   Clinical trial update

   24h Move

   -25.0%

   Positive interim Phase 2b data for Halneuron in chemotherapy neuropathic pain.

2. Dec 02

   IP / exclusivity

   24h Move

   -2.0%

   New synthetic Halneuron IP filing projected to extend exclusivity to 2045.

3. Nov 11

   Trial enrollment

   24h Move

   +1.4%

   First 100 patients enrolled in Halneuron Phase 2b HALT-CINP trial.

4. Nov 06

   Earnings update

   24h Move

   -6.5%

   Q3 2025 loss of $15.7M and cash runway only through Q1 2026.

5. Oct 30

   Earnings date notice

   24h Move

   +7.8%

   Announcement of timing for upcoming Q3 2025 financial results release.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

registered direct offering, private placement, pre-funded warrants, warrants, +4 more

8 terms

registered direct offering financial

"gross proceeds through a registered direct offering (the “Registered Offering”)"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

private placement financial

"and a concurrent private placement (the “Private Offering”"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

pre-funded warrants financial

"shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

warrants financial

"together with warrants to purchase up to an aggregate of 4,386,037 shares"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

form s-3 regulatory

"pursuant to an effective shelf registration statement on Form S-3 (File No. 333-287575)"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"A prospectus supplement relating to the shares of common stock to be issued"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

section 4(a)(2) regulatory

"offered in a private placement under Section 4(a)(2) of the Act and Regulation D"

Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.

regulation d regulatory

"under Section 4(a)(2) of the Act and Regulation D promulgated thereunder"

Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement

Offerings priced at-the-market under Nasdaq rules

ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX” or “Company”), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for up to approximately $12.5 million in gross proceeds through a registered direct offering (the “Registered Offering”) and a concurrent private placement (the “Private Offering” and, together with the Registered Offering, the “Offerings”) for the issuance of an aggregate of 4,386,037 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate of 4,386,037 shares of common stock, priced at-the-market under Nasdaq rules. Each share of common stock (or pre-funded warrant in-lieu thereof) is being sold together with one warrant to purchase one share of common stock at a combined purchase price of $2.85 (or $2.8499 per pre-funded warrant and accompanying warrant). The warrants will have an exercise price of $3.28 per share. The warrants will be exercisable upon shareholder approval, and will expire five and one-half years from the effective date of shareholder approval. Upfront gross proceeds from the Offerings are expected to be $12.5 million, before deducting commissions and offering expenses, with the potential for an additional $14.4 million in gross proceeds upon the exercise of the warrants at the election of investors and subject to shareholder approval.

The Registered Offering consists of the issuance and sale of 2,338,948 shares of common stock, and the Private Offering consists of the issuance and sale of pre-funded warrants to purchase 2,047,089 shares of common stock and warrants to purchase up to 4,386,037 shares of common stock.

Greg Duncan, Chairman and CEO of DWTX, commented: “We plan to utilize the net proceeds from the Offering to advance development of Halneuron^® through the ongoing Phase 2b final data readout, while also pursuing strategic opportunities to further strengthen the Company’s research portfolio. We are executing with determination to advance the standard of care for patients suffering from chemotherapy induced pain and neuropathy, conditions for which there are no FDA approved treatments. This transaction represents a strong endorsement of our two first-in-class development candidates, Halneuron^® and SP16, our research progress, growing IP portfolio and the exceptional talent we’ve assembled. Today’s offering provides DWTX with access to additional capital to support Phase 3 development.”

Maxim Group LLC is acting as the sole placement agent for the Offerings.

The Company intends to use the net proceeds from this offering to further advance the clinical development of Halneuron^® and for working capital and general corporate purposes. The Offerings are expected to close on or about January 13, 2026 (the “Closing Date”), subject to the satisfaction of customary closing conditions.

The Registered Offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-287575) previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission (“SEC”) on June 2, 2025. The Registered Offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the effective shelf registration statement. A prospectus supplement relating to the shares of common stock to be issued in the Registered Offering will be filed by the Company with the SEC. When available, copies of the prospectus supplement relating to the Registered Offering, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov or by contacting Maxim Group LLC, at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or by telephone at (212) 895-3745.

The pre-funded warrants and warrants described above were offered in a private placement under Section 4(a)(2) of the Act and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. Pursuant to a securities purchase agreement, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock issuable upon exercise of the pre-funded warrants and warrants.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Dogwood Therapeutics

Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron^® and SP16 IV. Our lead product candidate, Halneuron^®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron^® has been granted fast track designation from the FDA for the treatment of CINP. Halneuron^® is a non-opioid, Na_V 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron^® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (“CINP”). SP16 IV is a low-density lipoprotein receptor related protein-1 agonist (LRP1) with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16 acts as an LRP1 agonist that in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b CINP trial is fully funded by the National Cancer Institute.

Dogwood Therapeutic’s largest shareholder is a member of CK Life Sciences Int’l., (Holdings) Inc., which is listed on the Hong Kong Stock Exchange (Stock code: 0775). For more information, please visit www.dwtx.com.

Forward-Looking Statements:
Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the timing and consummation of the Offerings, and the completion, timing and results of current and future clinical studies relating to Dogwood’s product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2024, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.

Investor Relations:
CORE IR
(516) 222-2560
IR@dwtx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much immediate financing did Dogwood Therapeutics (DWTX) announce on Jan 12, 2026?

Dogwood announced upfront gross proceeds of $12.5 million from the registered direct and private offerings.

What is the total potential capital Dogwood (DWTX) could raise including warrants?

Including warrant exercises, Dogwood could raise up to $26.9 million in total gross proceeds ($12.5M upfront plus $14.4M upon exercise).

What securities did Dogwood (DWTX) issue and at what price per unit?

The company issued or will issue 4,386,037 common shares (or pre-funded warrants) paired with warrants at a combined purchase price of $2.85 per unit.

What is the warrant exercise price and exercisability condition for DWTX warrants?

Warrants have an exercise price of $3.28 per share and are exercisable only after shareholder approval and expire 5.5 years after approval.

How will Dogwood (DWTX) use the net proceeds from the offering?

Net proceeds are intended to advance Halneuron through Phase 2b, support Phase 3 planning, and for working capital and general corporate purposes.

When is the Dogwood (DWTX) offering expected to close?

The Offerings are expected to close on or about January 13, 2026, subject to customary closing conditions.